Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combination of Therabest’s iPSC derived NK cell therapy TB-100 and Glycotope’s tumor-targeted immuno-cytokine GT-00AxIL15 challenges the current NK cell therapy paradigm by converging a two-component platform improves the activity of TB-100.
Lead Product(s): TB-100,GT-00AxIL15
Therapeutic Area: Oncology Product Name: TB-100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Glycotope
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022